Predictive value of absolute CD4 cell count for disease progression in untreated HIV-1-infected children
- 12 June 2006
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 20 (9) , 1289-1294
- https://doi.org/10.1097/01.aids.0000232237.20792.68
Abstract
To describe the relationship between absolute CD4 cell count and the short-term risk of disease progression in HIV-1-infected children. A meta-analysis of individual longitudinal data on HIV-1-infected children enrolled in trials and cohort studies in Europe and the USA. The risks of progression to death and AIDS (or death) within 12 months, in terms of age and the most recent CD4 cell count, were estimated using parametric survival models. The analysis was restricted to measurements before the start of antiretroviral therapy except zidovudine monotherapy. The values of the absolute CD4 cell count and percentage predicting selected levels of disease progression risk were determined from this and previous models. A total of 566 deaths was observed over 9128 person-years of follow-up, and 992 children progressed to AIDS or death over 7309 person-years of follow-up. In children older than 4 or 5 years, the estimated risk of disease progression increased sharply when the CD4 cell count fell below 200-300 cells/microl. As with other immunological markers, CD4 cell count was less prognostic in younger children. The CD4 cell count values predicting a 12-month risk of death of 2-5% and of AIDS of 5-10% were much more strongly influenced by age than equivalent CD4 cell percentage values. This study suggests it may be appropriate to extend CD4 cell count criteria for initiating antiretroviral therapy in HIV-1-infected adults to children as young as 4 or 5 years. Monitoring by CD4 cell count in younger children is problematical because age is a highly influential variable.Keywords
This publication has 8 references indexed in Scilit:
- Use of total lymphocyte count for informing when to start antiretroviral therapy in HIV-infected children: a meta-analysis of longitudinal dataThe Lancet, 2005
- PENTA guidelines for the use of antiretroviral therapy, 2004HIV Medicine, 2004
- Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy eraAIDS, 2004
- Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysisThe Lancet, 2003
- When should antiretroviral therapy be started for HIV infection? Interpreting the evidence from observational studiesAIDS, 2003
- Five year follow up of vertically HIV infected children in a randomised double blind controlled trial of immediate versus deferred zidovudine: the PENTA 1 trialArchives of Disease in Childhood, 2001
- Incorporating correlations between measurements into the estimation of age-related reference rangesStatistics in Medicine, 1998
- Predictive Value of Quantitative Plasma HIV RNA and CD4+ Lymphocyte Count in HIV-Infected Infants and ChildrenPublished by American Medical Association (AMA) ,1998